Is Gilteritinib a targeted drug?

Gilteritinib is a targeted drug. Its mechanism of action is to interfere with abnormal signaling pathways in leukemia cells by inhibiting the activity of FLT3 receptor tyrosine kinase. The FLT3 receptor tyrosine kinase regulates cell growth and differentiation in normal cells, but in patients with FLT3 mutation-positive acute myeloid leukemia (AML), the FLT3 gene is mutated, leading to abnormal activation of the FLT3 receptor and promoting abnormal proliferation and growth of leukemia cells. Therefore, it is considered a targeted therapy that acts more specifically on leukemia cells without having a significant impact on normal cells. Compared with traditional chemotherapy methods, targeted therapy usually has lower toxic side effects.